Herpesvirus Antiviral Resistance
Database


    • TOP

    Cidofovir

    Assays:

    Mutant Gene Type Virus EC50 ratio Phenotype Assay Reference
    Q229K UL54 SNP Human betaherpesvirus 5 1.00 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    D247N UL54 SNP Human betaherpesvirus 5 0.90 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    D262N UL54 SNP Human betaherpesvirus 5 1.00 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    D271A UL54 SNP Human betaherpesvirus 5 1.10 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    D288N UL54 SNP Human betaherpesvirus 5 1.20 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    D301N UL54 SNP Human betaherpesvirus 5 3.00 Intermediate level resistance Details Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
    E303G UL54 SNP Human betaherpesvirus 5 20.00 High level resistance Details Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    E303D UL54 SNP Human betaherpesvirus 5 16.00 High level resistance Details Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    F396L UL54 SNP Human betaherpesvirus 5 1.50 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    N408H UL54 SNP Human betaherpesvirus 5 3.30 Intermediate level resistance Details Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    N408D UL54 SNP Human betaherpesvirus 5 5.60 High level resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    N408K UL54 SNP Human betaherpesvirus 5 21.00 High level resistance Details Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates. (Jan 2007)
    N408S UL54 SNP Human betaherpesvirus 5 7.50 High level resistance Details Novel DNA polymerase mutations conferring cytomegalovirus resistance: input of BAC-recombinant phenotyping and 3D model. (Apr 2013)
    N410K UL54 SNP Human betaherpesvirus 5 3.00 Intermediate level resistance Details Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
    F412C UL54 SNP Human betaherpesvirus 5 18.00 High level resistance Details Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. (Sep 1997)
    F412L UL54 SNP Human betaherpesvirus 5 9.40 High level resistance Details Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy. (Apr 2011)
    F412S UL54 SNP Human betaherpesvirus 5 13.00 High level resistance Details Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy. (Apr 2011)
    F412V UL54 SNP Human betaherpesvirus 5 15.50 High level resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    D413A UL54 SNP Human betaherpesvirus 5 11.00 High level resistance Details Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients. (Feb 2007)
    D413E UL54 SNP Human betaherpesvirus 5 4.30 Intermediate level resistance Details Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
    D413N UL54 SNP Human betaherpesvirus 5 10.00 High level resistance Details Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    D413del UL54 in/del Human betaherpesvirus 5 5.80 High level resistance Details Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    D413Y UL54 SNP Human betaherpesvirus 5 9.30 High level resistance Details Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    L424V UL54 SNP Human betaherpesvirus 5 1.30 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    F460L UL54 SNP Human betaherpesvirus 5 1.20 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    V476G UL54 SNP Human betaherpesvirus 5 0.90 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    P488R UL54 SNP Human betaherpesvirus 5 7.90 High level resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    A492D UL54 SNP Human betaherpesvirus 5 1.36 No resistance Details Identification of resistance-associated HCMV UL97- and UL54-mutations and a UL97-polymporphism with impact on phenotypic drug-resistance. (Jul 2016)
    N495K UL54 SNP Human betaherpesvirus 5 1.10 No resistance Details A novel mutation in the UL54 gene of human cytomegalovirus isolates that confers resistance to foscarnet. ( 2006)
    K500N UL54 SNP Human betaherpesvirus 5 3.00 Intermediate level resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    L501F UL54 SNP Human betaherpesvirus 5 3.80 Intermediate level resistance Details Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    L501I UL54 SNP Human betaherpesvirus 5 9.10 High level resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    T503A UL54 SNP Human betaherpesvirus 5 3.70 Intermediate level resistance Details Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    T503I UL54 SNP Human betaherpesvirus 5 6.10 High level resistance Details Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
    A505V UL54 SNP Human betaherpesvirus 5 2.00 Low level resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    K513Q UL54 SNP Human betaherpesvirus 5 18.00 High level resistance Details Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    K513E UL54 SNP Human betaherpesvirus 5 9.10 High level resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    K513N UL54 SNP Human betaherpesvirus 5 12.50 High level resistance Details A point mutation in the human cytomegalovirus DNA polymerase gene selected in vitro by cidofovir confers a slow replication phenotype in cell culture. (Sep 1998)
    K513R UL54 SNP Human betaherpesvirus 5 10.00 High level resistance Details Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    D515E UL54 SNP Human betaherpesvirus 5 1.60 No resistance Details Drug-resistant human cytomegalovirus infection in children after allogeneic stem cell transplantation may have different clinical outcomes. (Nov 2000)
    D515Y UL54 SNP Human betaherpesvirus 5 0.87 No resistance Details Contrasting effect of new HCMV pUL54 mutations on antiviral drug susceptibility: Benefits and limits of 3D analysis. (May 2016)
    L516R UL54 SNP Human betaherpesvirus 5 5.10 High level resistance Details Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
    L516W UL54 SNP Human betaherpesvirus 5 8.49 High level resistance Details Identification of resistance-associated HCMV UL97- and UL54-mutations and a UL97-polymporphism with impact on phenotypic drug-resistance. (Jul 2016)
    I521T UL54 SNP Human betaherpesvirus 5 5.10 High level resistance Details Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus. (Sep 2008)
    P522T UL54 SNP Human betaherpesvirus 5 2.00 Low level resistance Details Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    P522A UL54 SNP Human betaherpesvirus 5 4.10 Intermediate level resistance Details Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus. (Sep 2008)
    P522S UL54 SNP Human betaherpesvirus 5 3.60 Intermediate level resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    C524del UL54 in/del Human betaherpesvirus 5 9.70 High level resistance Details Novel DNA polymerase mutations conferring cytomegalovirus resistance: input of BAC-recombinant phenotyping and 3D model. (Apr 2013)
    V526L UL54 SNP Human betaherpesvirus 5 2.50 Low level resistance Details Characterization of multiple cytomegalovirus drug resistance mutations detected in a hematopoietic stem cell transplant recipient by recombinant phenotyping. (Nov 2014)
    C539G UL54 SNP Human betaherpesvirus 5 4.40 Intermediate level resistance Details Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    C539R UL54 SNP Human betaherpesvirus 5 13.30 High level resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    D542E UL54 SNP Human betaherpesvirus 5 12.00 High level resistance Details Selection and recombinant phenotyping of a novel CMX001 and cidofovir resistance mutation in human cytomegalovirus. (Jul 2013)
    A543S UL54 SNP Human betaherpesvirus 5 1.00 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    L545F UL54 SNP Human betaherpesvirus 5 11.00 High level resistance Details Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    L545S UL54 SNP Human betaherpesvirus 5 9.10 High level resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    L545W UL54 SNP Human betaherpesvirus 5 6.30 High level resistance Details Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy. (Apr 2011)
    T552N UL54 SNP Human betaherpesvirus 5 1.20 No resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    Q578H UL54 SNP Human betaherpesvirus 5 2.30 Low level resistance Details Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy. (Apr 2011)
    Q578L UL54 SNP Human betaherpesvirus 5 0.80 No resistance Details Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    S585A UL54 SNP Human betaherpesvirus 5 1.40 No resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    D588E UL54 SNP Human betaherpesvirus 5 1.10 No resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    D588N UL54 SNP Human betaherpesvirus 5 2.70 Low level resistance Details How evolution of mutations conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus-infected hematopoietic cell transplant recipients. (Jan 2005)
    C590F UL54 SNP Human betaherpesvirus 5 1.60 No resistance Details Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    F595I UL54 SNP Human betaherpesvirus 5 1.20 No resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    V654G UL54 SNP Human betaherpesvirus 5 1.10 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    S660G UL54 SNP Human betaherpesvirus 5 0.90 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    G667N UL54 SNP Human betaherpesvirus 5 0.80 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    A692G UL54 SNP Human betaherpesvirus 5 0.90 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    T700A UL54 SNP Human betaherpesvirus 5 1.50 No resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    V715A UL54 SNP Human betaherpesvirus 5 0.47 Possible hypersensitivity, no resistance Details Identification of resistance-associated HCMV UL97- and UL54-mutations and a UL97-polymporphism with impact on phenotypic drug-resistance. (Jul 2016)
    V715M UL54 SNP Human betaherpesvirus 5 1.10 No resistance Details Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS. (Mar 1996)
    I726T UL54 SNP Human betaherpesvirus 5 1.70 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    I726V UL54 SNP Human betaherpesvirus 5 1.90 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    E756D UL54 SNP Human betaherpesvirus 5 0.70 No resistance Details Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
    E756K UL54 SNP Human betaherpesvirus 5 2.20 Low level resistance Details Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
    E756Q UL54 SNP Human betaherpesvirus 5 1.00 No resistance Details Mutations conferring foscarnet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. (Mar 2003)
    L773V UL54 SNP Human betaherpesvirus 5 2.50 Low level resistance Details Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    L776M UL54 SNP Human betaherpesvirus 5 1.00 No resistance Details Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation. (May 2008)
    V781I UL54 SNP Human betaherpesvirus 5 1.20 No resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    V787A UL54 SNP Human betaherpesvirus 5 Details Rapid detection of human cytomegalovirus UL97 and UL54 mutations for antiviral resistance in clinical specimens. (May 2013)
    V787E UL54 SNP Human betaherpesvirus 5 2.90 Low level resistance Details Compartmentalization of a Multidrug-Resistant Cytomegalovirus UL54 Mutant in a Stem Cell Transplant Recipient with Encephalitis. (Sep 2019)
    V787L UL54 SNP Human betaherpesvirus 5 1.00 No resistance Details Mutations conferring foscarnet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. (Mar 2003)
    E793V UL54 SNP Human betaherpesvirus 5 0.70 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    Q795P UL54 SNP Human betaherpesvirus 5 0.90 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    Q795R UL54 SNP Human betaherpesvirus 5 0.90 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    L802M UL54 SNP Human betaherpesvirus 5 0.90-1.80 Range of values of No resistance Details Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. (Sep 1997)
    L802V UL54 SNP Human betaherpesvirus 5 1.10 No resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    K805Q UL54 SNP Human betaherpesvirus 5 2.20 Low level resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    A809V UL54 SNP Human betaherpesvirus 5 1.70 No resistance Details Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    V812L UL54 SNP Human betaherpesvirus 5 3.20 Intermediate level resistance Details A point mutation in the human cytomegalovirus DNA polymerase gene selected in vitro by cidofovir confers a slow replication phenotype in cell culture. (Sep 1998)
    T813S UL54 SNP Human betaherpesvirus 5 2.90 Low level resistance Details Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens. (Nov 2007)
    T821I UL54 SNP Human betaherpesvirus 5 1.90 No resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    M827I UL54 SNP Human betaherpesvirus 5 0.70 No resistance Details Analysis of Mutations in the Gene Encoding Cytomegalovirus DNA Polymerase in a Phase 2 Clinical Trial of Brincidofovir Prophylaxis. (Jul 2016)
    P829S UL54 SNP Human betaherpesvirus 5 1.60 No resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    A834P UL54 SNP Human betaherpesvirus 5 3.00 Intermediate level resistance Details Cytomegalovirus antiviral resistance associated with treatment induced UL97 (protein kinase) and UL54 (DNA polymerase) mutations. (Sep 2004)
    T838A UL54 SNP Human betaherpesvirus 5 0.80 No resistance Details How evolution of mutations conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus-infected hematopoietic cell transplant recipients. (Jan 2005)
    G841S UL54 SNP Human betaherpesvirus 5 1.10 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    G841A UL54 SNP Human betaherpesvirus 5 2.60 Low level resistance Details Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens. (Nov 2007)
    M844T UL54 SNP Human betaherpesvirus 5 1.30 No resistance Details Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure. (Jan 2012)
    M844V UL54 SNP Human betaherpesvirus 5 1.60 No resistance Details Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure. (Jan 2012)
    P859A UL54 SNP Human betaherpesvirus 5 1.00 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    L862F UL54 SNP Human betaherpesvirus 5 0.90 No resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    V902G UL54 SNP Human betaherpesvirus 5 1.00 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    V946L UL54 SNP Human betaherpesvirus 5 0.90 No resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    K947E UL54 SNP Human betaherpesvirus 5 1.00 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    L957F UL54 SNP Human betaherpesvirus 5 1.40 No resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    M959T UL54 SNP Human betaherpesvirus 5 0.90 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    981-982del UL54 in/del Human betaherpesvirus 5 4.20 Intermediate level resistance Details Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    D981del UL54 in/del Human betaherpesvirus 5 2.80 Low level resistance Details A deletion mutation in region V of the cytomegalovirus DNA polymerase sequence confers multidrug resistance. (Dec 2000)
    A987G UL54 SNP Human betaherpesvirus 5 11.30 High level resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)